Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
261-280 of 2,120 trials

Prostate Cancer: Long-Term Safety of Lutetium (177Lu) Treatment

We are investigating the long-term safety of lutetium (177Lu) vipivotide tetraxetan in adults with prostate cancer. This study aims to identify potential risks and serious side effects over time.

Prostate Cancer>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

PDA Treatment in Premature Infants: Acetaminophen and Ibuprofen Study

We are studying whether combining acetaminophen with ibuprofen helps extremely premature infants with a heart condition. The goal is to see if this combination reduces serious complications compared to ibuprofen alone.

Patent Ductus Arteriosus≤3 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesCardiologyPediatrics

Systemic Sclerosis-Associated Lung Disease: Belimumab Study

We are testing whether belimumab can improve lung function and reduce skin thickening in adults with systemic sclerosis-related lung disease. This study compares its effects to a placebo alongside standard treatment.

Systemic Sclerosis Associated Interstitial Lung Disease1-2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPulmonologyRheumatology

Advanced Non-Small Cell Lung Cancer: Cemiplimab and BNT116 Combination

We are studying how a new cancer vaccine combined with cemiplimab works for adults with advanced non-small cell lung cancer. This trial will help us understand its effectiveness and safety compared to cemiplimab alone.

Advanced Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesPartially RemoteOncology

Atrial Fibrillation: Abelacimab Treatment Study

We are studying whether abelacimab can help high-risk patients with atrial fibrillation who cannot take oral blood thinners. The goal is to see if it reduces the risk of strokes and other serious complications compared to a placebo.

Atrial Fibrillation>2 yearsConfirmation phase (III)>20 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Colorectal Cancer: Flu Vaccine and Pembrolizumab Study

We are exploring whether a flu vaccine combined with pembrolizumab can help shrink tumors in patients with early pMMR colorectal cancer. The study will also assess safety and immune responses.

Colorectal Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Pleural Mesothelioma: Volrustomig with Carboplatin and Pemetrexed

We are studying a new treatment combination for patients with unresectable pleural mesothelioma. The goal is to see if it works better than current standard care options.

Unresectable Pleural Mesothelioma>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Ureter Visualization: Nizaracianine Triflutate in Surgery

We are studying a new intravenous drug to help surgeons see the ureters more clearly during abdominopelvic surgeries. This may improve safety and reduce the need for invasive procedures.

Urinary Tract ImagingEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesOtolaryngologyUrology

Endometrial Cancer: RAINBO Treatment Study

We are exploring a new treatment approach for patients with endometrial cancer based on their molecular features. The goal is to see if this can improve survival rates and reduce the chance of cancer returning.

Mismatch Repair Deficient High-Risk Endometrial Cancer>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesGynecology and ObstetricsOncology

Postpartum Anemia: IV vs. Oral Iron Treatment

We are studying whether intravenous iron is more effective than oral iron in reducing postpartum depression and improving anemia in women after cesarean delivery. This trial will help us understand the best treatment options for new mothers facing these challenges.

Postpartum Depression with Iron Deficiency Anemia>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesGynecology and ObstetricsPsychiatry

Melanoma Treatment: ABP 206 vs. OPDIVO

We are evaluating a new treatment, ABP 206, for patients with advanced melanoma who have not been treated before. The study aims to see how well it works and how safe it is compared to OPDIVO.

Metastatic Melanoma>2 yearsConfirmation phase (III)>20 visitsNo PlaceboInvestigational MedicinesPartially RemoteOncology

Bronchiectasis: Long-Term Study of BI 1291583

We are testing the long-term safety of BI 1291583 in people with bronchiectasis who have taken part in earlier studies. The study will also look at whether this treatment helps reduce lung flare-ups.

Bronchiectasis>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemotePulmonology

Osteogenesis Imperfecta: Romosozumab vs. Bisphosphonates

We are studying whether romosozumab can reduce fractures and improve bone density in children and adolescents with osteogenesis imperfecta compared to bisphosphonates. This trial will help us understand the safety and effectiveness of this new treatment.

Brittle Bone Disease1-2 yearsConfirmation phase (III)16-20 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOrthopedics and TraumatologyPediatrics

Biliary Tract Cancer: GAP Chemotherapy Study

We are studying whether a combination of chemotherapy before surgery helps patients with biliary tract cancers live longer and have better outcomes than those who undergo surgery right away.

Biliary Tract CancerEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesOncology

Metastatic Non-Small Cell Lung Cancer: Volrustomig Plus Chemotherapy

We are studying whether the new drug volrustomig combined with chemotherapy is more effective than pembrolizumab plus chemotherapy for patients with metastatic non-small cell lung cancer. This trial focuses on those with low PD-L1 levels.

Metastatic Non-Small Cell Lung Cancer≤3 monthsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Tislelizumab for Cancer Patients with Residual Disease

We are studying whether tislelizumab can help cancer patients who still have detectable disease after standard treatment. The goal is to see if it improves their chances of staying cancer-free compared to a placebo.

Pancreatic CancerSoft Tissue SarcomaNon-Small Cell Lung Cancer>2 yearsConfirmation phase (III)16-20 visitsStandard MedicinesPartially RemoteGastroenterologyOncologyPulmonology

Metastatic Renal Cell Carcinoma: Treatment Comparison Study

We are comparing two treatment combinations for patients with metastatic renal cell carcinoma to see which one improves survival and quality of life. This study is for those who have not received treatment before and have specific risk factors.

Metastatic Renal Cell CarcinomaConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesInternal MedicineOncology

Oligometastatic Non-Small Cell Lung Cancer: Immunotherapy with Local Treatments

We are studying whether adding a local treatment to standard immunotherapy helps improve survival for patients with oligometastatic non-small cell lung cancer. This trial will also look at quality of life and side effects.

Synchronous Oligometastatic Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesOncologyPulmonology

Lung Cancer Treatment: MK-2870 with Pembrolizumab

We are comparing a new combination treatment for metastatic non-small cell lung cancer to standard therapy. This study aims to see if the combination improves survival and quality of life for patients with high PD-L1 levels.

Metastatic Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesOncology

Ovarian Cancer Diagnosis: IMPROCAS Study

We are exploring new blood test methods and imaging techniques to improve how ovarian cancer is diagnosed. This study aims to create a better model for identifying the disease and understanding its severity.

Ovarian CancerEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesGynecology and ObstetricsInternal MedicineOncology